Khalid O Dar - Internal Medicine | Mount Sinai

About Me

I have been on staff at St. Luke’s Hospital since 1995 and have dedicated almost my entire career in serving the patients and community of St. Luke’s. I was initially involved in training fellows in the Hematology/Oncology fellowship program at St. Luke’s Hospital and subsequently served as a voluntary attending physician in private practice.

I am proud of the affiliation with Mount Sinai particularly now that the Tisch Cancer Institute at Mount Sinai has received NCI designation as a Clinical Cancer Center. I have always been focused on providing personalized, compassionate care and now with the close association with Mount Sinai my patients will have access to the most up-to-date research, diagnostic tools and therapies available.

Language

English, Urdu (Pakistan), Indian (Hindi)

Position

ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology

Hospital Affiliations

Mount Sinai Morningside
Mount Sinai Beth Israel
Mount Sinai Brooklyn
Mount Sinai Queens
The Mount Sinai Hospital
Mount Sinai West

Clinical Focus

Breast Cancer
Colorectal Cancer
Gastric (Stomach) Cancer
Hematologic Malignancies
Hematology
Lung Cancer
Myelodysplastic Syndromes
Myeloproliferative Disorders
Pancreatic Cancer

Education

MBBS, Charing Cross & Westminster Medical School

Residency, Surgery (General Surgery)

Queen Mary's Hospital

Residency, General Practice

St. Helier Hospital

Residency, Internal Medicine

Princess Margaret Hospital

Residency, Internal Medicine

Joyce Green Hospital

Residency, Internal Medicine

Staten Island University Hospital

Fellowship, Hematology & Oncology

Mount Sinai Hospital

Certifications

American Board of Internal Medicine

Research

As a fellow my research project focused on the drug development of the topoisomerase I inhibitor topotecan. Using Western Blot assays I quantified the topoisomerase I copy numbers in a variety of human tumors to identify potential cancers that may be susceptible to this therapy. I was also involved in developing a mouse in vivo system for combination immuno-chemotherapy using xenografts of human mammary tumors in mice.

Locations

Mount Sinai Morningside

440 West 114th Street, Clark Bldg, 6th Floor, New York, NY, 10025

212-523-8570

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.

Mount Sinai Morningside440 West 114th Street, Clark Bldg, 6th Floor, New York, NY, 10025

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Publications:1

Selected Publications

Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Leonard Liebes, Milan Potmesil, Tony Kim, Denise Pease, Michael Buckley, David Fry, John Cho, Howard Adler, Khalid Dar, Anne Zeleniuch-Jacquotte, Howard Hochster. Clinical Cancer Research

View All Publications

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Dar has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Khalid O Dar, MD

Internal Medicine, Cancer (Oncology), Hematology-Oncology

About Me

Language

Position

Hospital Affiliations

About Me

Language

Position

Hospital Affiliations

Clinical Focus

Education

MBBS, Charing Cross & Westminster Medical School

Residency, Surgery (General Surgery)

Residency, General Practice

Residency, Internal Medicine

Residency, Internal Medicine

Residency, Internal Medicine

Fellowship, Hematology & Oncology

Certifications

American Board of Internal Medicine

Research

Locations

Mount Sinai Morningside

Insurance Information

Publications

Selected Publications

Industry Relationships